Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 6/20 | 0.39 |
| ▸ | CNR1 | P21554 | 4/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 4/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | GAA | P10253 | 3/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 3/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | GLA | P06280 | 2/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3995619 | 0.88 | CNR2 (0.38) | CNR2CNR1NPC1RAB9AHPGD | |
| SCHEMBL29065098 | 0.81 | ALDH1A1 (0.43) | CNR2CNR1NPC1RAB9AALDH1A1 | |
| SCHEMBL3998515 | 0.81 | CNR2 (0.42) | CNR2CNR1HPGDKDM4EALDH1A1 | |
| SCHEMBL4612812 | 0.76 | NR1H2 (0.39) | CNR2CNR1NPC1RAB9AHPGD | |
| SCHEMBL11728742 | 0.75 | MAOB (0.54) | NPC1RAB9AHPGDHSD17B10TSHR | |
| SCHEMBL28716486 | 0.72 | NPC1 (0.46) | NPC1RAB9AHPGDALDH1A1GAA | |
| SCHEMBL11463498 | 0.71 | NPC1 (0.46) | CNR2NPC1RAB9AHPGDKDM4E | |
| SCHEMBL10512990 | 0.71 | CNR2 (0.41) | CNR2CNR1NPC1RAB9AKDM4E | |
| SCHEMBL25392828 | 0.71 | CNR2 (0.48) | CNR2CNR1KDM4EALDH1A1GAA | |
| SCHEMBL12441571 | 0.71 | CNR2 (0.51) | CNR2CNR1HPGDKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7473703-B2 | Heterocyclic arylsulfonamidobenzylic compounds | AMGEN INC. (US) | 2009-01-06 | — | — | US | disclosed |
| US-7326812-B2 | Lipid diseases; metabolism diosrders; antiproliferative agents | AMGEN INC. (US) | 2008-02-05 | — | — | US | disclosed |
| US-20060270718-A1 | Heterocyclic arylsulfonamidobenzylic compounds | AMGEN, INC. | 2006-11-30 | — | — | US | disclosed |
| US-7112606-B2 | Heterocyclic arylsulfonamidobenzylic compounds | AMGEN INC. (US) | 2006-09-26 | — | — | US | disclosed |
| US-7071358-B2 | Arylsulfonamidobenzylic compounds | AMGEN INC. (US) | 2006-07-04 | — | — | US | disclosed |
| US-20060122239-A1 | Arylsulfonamidobenzylic compounds | TULARIK INC. | 2006-06-08 | — | — | US | disclosed |
| EP-1476423-A4 | ARYLSULFONAMIDOBENZYLIC COMPOUNDS | TULARIK INC (US) | 2005-12-14 | — | — | EP | disclosed |
| EP-1476423-A2 | ARYLSULFONAMIDOBENZYLIC COMPOUNDS | Tularik Inc. (US) | 2004-11-17 | — | — | EP | disclosed |
| US-20030229093-A1 | Arylsulfonamidobenzylic compounds | TULARIK INC. | 2003-12-11 | — | — | US | disclosed |
| US-20030220339-A1 | Useful in treating lipid disorders, metabolic disorders and cell-proliferative diseases | TULARIK INC. | 2003-11-27 | — | — | US | disclosed |
| WO-2003063576-A2 | ARYLSULFONAMIDOBENZYLIC COMPOUNDS | TULARIK INC. (US) | 2003-08-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030220339-A1 | Useful in treating lipid disorders, metabolic disorders and cell-proliferative diseases | HSD17B4, PLIN1, PNLIP | CNR2 2287/4885CNR1 2241/4885NPC1 65/4885 |
| US-20060122239-A1 | Arylsulfonamidobenzylic compounds | FASN, ARSA, HSD17B4 | CNR2 1648/4885CNR1 1800/4885NPC1 177/4885 |
| US-20030229093-A1 | Arylsulfonamidobenzylic compounds | FASN, ARSA, HSD17B4 | CNR2 1648/4885CNR1 1800/4885NPC1 177/4885 |
| US-20060270718-A1 | Heterocyclic arylsulfonamidobenzylic compounds | ACACB, HSD17B4, ACSS2 | CNR2 2054/4885CNR1 1999/4885NPC1 43/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.